Most recently Urban Paulsson comes from Camurus AB, where he worked as VP Corporate Development. His current assignment includes board work within various life science companies in both listed and unlisted environments. In connection with Paulsson’s previous entry into Lipigon’s board, he also became one of Lipigon’s major owners through his investment company.
“Lipigon is a very exciting company, and I appreciate the trust to take over the chairmanship. I look forward to, together with the rest of the board, continuing to support the management in its work to take the company to the next level. The board would like to thank Carina Schmidt, who during her time as chairman has contributed valuable contributions to Lipigon’s development”, says Urban Paulsson.
“We are happy that Urban Paulsson will be our new chairman when Carina Schmidt chooses to leave. Lipigon is in an important growth phase and I am convinced that Urban, with its experience from listed life science companies and involvement as a major owner, will drive significant issues forward”, says Stefan K Nilsson, CEO of Lipigon.
Lipigon, which is located at the Umeå Biotech Incubator, develops medicines for lipid-related disorders, i.e. diseases caused by irregularities when fats are processed in the body. Of these the most well-known is cholesterol and the role it plays in the development of cardiovascular disease, but fats can also contribute to various liver diseases, type 2 diabetes and a number of rare so-called ‘orphan drug’ diseases.
For more information, please contact:
Stefan K Nilsson, CEO of Lipigon
+46 70 578 17 68
About Lipigon Pharmaceuticals
Lipigon develops new treatments for diseases caused by disorders in the body’s handling of fats, so-called lipid-related diseases. The company’s operations are based on over 50 years of lipid research at Umeå University. Lipigon’s initial focus is on orphan drugs and niche indications that can then be further developed for broader indications such as diabetes and cardiovascular disease. Lipigon’s pipeline consists of four active programs; RNA drug Lipisense, targeting elevated triglycerides; RNA drugs for acute respiratory distress syndrome; a gene therapy project for the rare disease lipodystrophy together with Combigene AB (publ); and a small molecule project for dyslipidemia (general lipid disorders) in collaboration with HitGen, Inc.